An interdisciplinary research team at The University of Texas at San Antonio has successfully developed an innovative inhibitor that shows promise in fighting obesity and potentially preventing heart disease..The team has developed an anti-obesity drug that blocks the effects of cytochrome P450-8B 1 an enzyme that creates cholic acid in the body. This inhibition decreases cholesterol absorption. This process may hold the key to treating obesity-associated metabolic disorders and other diseases linked to obesity, such as heart disease and Diabetes. Though the drug inhibits cholesterol absorption, scientists are still unravelling how this could impact blood glucose level.The team's research included treating mice with the inhibitor drug for seven days. The result was a decrease in the levels of blood glucose levels despite having been fed a high-fat and high-sucrose diet - without affects to their body weight. The results demonstrate how a P450-8B 1 inhibitor could lead to a healthier metabolic profile and its potential could lead to developing a therapeutic strategy to treat obesity-associated insulin resistance.
An interdisciplinary research team at The University of Texas at San Antonio has successfully developed an innovative inhibitor that shows promise in fighting obesity and potentially preventing heart disease..The team has developed an anti-obesity drug that blocks the effects of cytochrome P450-8B 1 an enzyme that creates cholic acid in the body. This inhibition decreases cholesterol absorption. This process may hold the key to treating obesity-associated metabolic disorders and other diseases linked to obesity, such as heart disease and Diabetes. Though the drug inhibits cholesterol absorption, scientists are still unravelling how this could impact blood glucose level.The team's research included treating mice with the inhibitor drug for seven days. The result was a decrease in the levels of blood glucose levels despite having been fed a high-fat and high-sucrose diet - without affects to their body weight. The results demonstrate how a P450-8B 1 inhibitor could lead to a healthier metabolic profile and its potential could lead to developing a therapeutic strategy to treat obesity-associated insulin resistance.
